Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
about
A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells.Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis.Modulating inflammation and neuroprotection in multiple sclerosis.Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.Metabolic pathways as possible therapeutic targets for progressive multiple sclerosis.Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.Long-term follow-up more than 10 years after HSCT: a monocentric experience.Preserving the independence of people living with multiple sclerosis towards the end of life.Targets of therapy in progressive MS.Cell-based therapeutic strategies for multiple sclerosis.Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis.To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question.A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis.Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant.Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.
P2860
Q38376686-8F2AF4AB-4F4E-4EAA-976C-6BDDD99D007AQ38739510-7B3E98DA-AA53-4D61-9050-CB5A240477C5Q39350409-616F331A-61F6-4C18-9B4F-6F836E1385E8Q39378263-DD506B87-ED7D-4B51-AE28-2B1323B5B3ACQ40177200-D3832D67-AED3-42D6-B747-6BCB1EF44358Q42361828-78770A96-BE91-4039-A7BA-B68F707AFA43Q46301560-23205FD8-3F7F-42A4-8EFD-EF09F00BE32CQ47261875-0779EF1C-4828-437D-ADE2-0E63DECDDC58Q47566185-007DB819-D1EE-487D-B354-3458DCF6E8AEQ47774503-6C9F6E3D-0BF0-4137-AFE1-069DC104A73FQ47885870-B8FAABEA-06F8-4D05-B703-5B48342A7995Q48213823-A260FD1F-29DE-4D4C-969D-A22AA3343107Q48307050-54D49733-F036-44AC-98BF-4B5FD5A76D15Q49169217-3C56A349-7BA1-476A-B1BE-EEBE15AAC286Q52624498-90666150-F289-457C-9CF5-6ACF6A388EB1Q54960016-3129F1F4-F2CD-424D-B26D-3685C52FA14F
P2860
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Long-term Outcomes After Autol ...... tation for Multiple Sclerosis.
@en
type
label
Long-term Outcomes After Autol ...... tation for Multiple Sclerosis.
@en
prefLabel
Long-term Outcomes After Autol ...... tation for Multiple Sclerosis.
@en
P2093
P2860
P50
P1433
P1476
Long-term Outcomes After Autol ...... tation for Multiple Sclerosis.
@en
P2093
Albert Saiz
Athanasios Fassas
Belinda Simoes
Daniela A Moraes
Dominique Farge
Eva Havrdova
George E Georges
Giovanni L Mancardi
Harold L Atkins
James D Bowen
P2860
P304
P356
10.1001/JAMANEUROL.2016.5867
P407
P577
2017-02-20T00:00:00Z